年轻人睡眠障碍的苯二氮䓬类治疗与药物过量风险的关联
该队列研究基于美国商业理赔数据库(MarketScan)2009年1月1日至2018年12月31日的数据,纳入10–29岁因睡眠障碍起始苯二氮䓬类(n=23084)或替代药物(曲唑酮、羟嗪、唑吡坦、扎来普隆、右佐匹克隆;n=66706)治疗的年轻人,随访6个月内诊断的药物过量。倾向评分调整后,苯二氮䓬类与药物过量风险升高相关(意向性分析HR 1.25,95%CI 1.03–1.51;按治疗分析HR 1.44,95%CI 1.14–1.80);近期有阿片类处方者关联更强(按治疗分析aHR 2.01,95%CI 1.24–3.25 vs 无近期阿片处方aHR 1.31,95%CI 1.00–1.70)。作者认为,治疗年轻人睡眠障碍时,药物过量是苯二氮䓬类的重要安全考量。
要点
- 10–29岁睡眠障碍起始苯二氮䓬类者6个月药物过量粗发生率为0.9%,替代药物起始者为0.8%。
- 倾向评分调整后,苯二氮䓬类 vs 替代药物的药物过量风险:意向性分析HR 1.25(95%CI 1.03–1.51),按治疗分析HR 1.44(95%CI 1.14–1.80)。
- 近期有阿片类处方者中苯二氮䓬类与药物过量关联更强:按治疗分析aHR 2.01(95%CI 1.24–3.25),无近期阿片处方者aHR 1.31(95%CI 1.00–1.70)。
- 6个月时仍在治疗的比例:苯二氮䓬类9.7%(95%CI 9.3%–10.1%),替代药物组12.3%(95%CI 12.1%–12.6%)。
- 作者认为,治疗年轻人睡眠障碍时药物过量是苯二氮䓬类的重要安全考量,尤其对近期有阿片类处方者。
适用人群与场景
- 美国商业理赔数据库(MarketScan)中10–29岁、有睡眠障碍诊断并起始苯二氮䓬类(n=23084)或替代药物(曲唑酮、羟嗪、唑吡坦、扎来普隆、右佐匹克隆;n=66706)治疗的年轻人,数据时段2009年1月1日至2018年12月31日。
- 新起始治疗定义为≥1年无苯二氮䓬类或替代药物处方。
研究设计与关键结果
- 研究类型:队列研究,基于美国商业理赔数据库(MarketScan),纳入10–29岁睡眠障碍起始苯二氮䓬类(n=23084;女性14444例[62.6%];平均[SD]年龄23[4.1]岁)或替代药物(n=66706;女性38446例[57.6%];平均[SD]年龄22[4.4]岁)治疗的年轻人,随访6个月内诊断的药物过量。
- 主要终点:倾向评分调整后,苯二氮䓬类 vs 替代药物的药物过量风险升高(意向性分析HR 1.25[95%CI 1.03–1.51];按治疗分析HR 1.44[95%CI 1.14–1.80])。
- 粗发生率:6个月药物过量苯二氮䓬类起始者0.9%,替代药物起始者0.8%。
- 按近期阿片类处方分层:近期有阿片类处方者按治疗分析aHR 2.01(95%CI 1.24–3.25),无近期阿片类处方者aHR 1.31(95%CI 1.00–1.70)。
- 6个月时仍在治疗的比例:苯二氮䓬类9.7%(95%CI 9.3%–10.1%),替代药物组12.3%(95%CI 12.1%–12.6%)。
证据类型、等级与局限
- 证据类型:队列研究(基于美国商业理赔数据库MarketScan)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,苯二氮䓬类与替代药物治疗常见睡眠障碍相比,与年轻人随后6个月内药物过量风险升高相关,尤其近期有阿片类处方者;治疗年轻人睡眠障碍时,药物过量是苯二氮䓬类的重要安全考量。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Benzodiazepines are prescribed for the treatment of adolescent sleep disorders; however, benzodiazepine overdoses occur, often in combination with opioids.
OBJECTIVE: To evaluate whether benzodiazepine treatment for sleep disorders, compared with alternative pharmacologic treatments (trazodone, hydroxyzine, zolpidem, zaleplon, and eszopiclone), is associated with increased risk of drug overdose for young people.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study included privately insured people 10 to 29 years of age identified from a US commercial claims database (MarketScan), from January 1, 2009, to December 31, 2018. Young people with a sleep disorder diagnosis initiating benzodiazepine (n = 23 084) or comparator pharmacologic treatments (n = 66 706) were included in the study. Statistical analysis was performed from November 1, 2021, to May 16, 2022.
EXPOSURES: New use of benzodiazepine treatment or comparator pharmacologic treatments (defined as ≥1 year without a prescription for benzodiazepine or comparator medications).
MAIN OUTCOMES AND MEASURES: Incident diagnosed drug overdoses were identified from inpatient and emergency department records within 6 months of treatment initiation. The propensity score-adjusted cumulative incidence of overdose and hazard ratios (HRs) were estimated with intention-to-treat (analyzed based on initial treatment) and as-treated analyses (added censoring at treatment discontinuation). Results were stratified by prior prescription opioid fill.
RESULTS: The cohort included 23 084 young people initiating benzodiazepine treatment (14 444 female participants [62.6%]; mean [SD] age, 23 [4.1] years) and 66 706 initiating a comparator treatment (38 446 female participants [57.6%]; mean [SD] age, 22 [4.4] years). Six months after treatment initiation, 9.7% (95% CI, 9.3%-10.1%) of benzodiazepine users and 12.3% (95% CI, 12.1%-12.6%) of the comparator group were still receiving treatment. The crude incidence of drug overdose at 6 months was 0.9% for benzodiazepine initiators and 0.8% for comparator treatment initiators. In adjusted analyses, an increased risk of drug overdose was associated with benzodiazepines vs comparator treatments (intention-to-treat analysis: HR, 1.25 [95% CI, 1.03-1.51]; as-treated analysis: HR, 1.44 [95% CI, 1.14-1.80]). This association was stronger among young people with a recent prescription opioid fill vs those without a recent prescription opioid fill (as-treated analysis: adjusted HR, 2.01 [95% CI, 1.24-3.25] vs adjusted HR, 1.31 [95% CI, 1.00-1.70]).
CONCLUSIONS AND RELEVANCE: The findings of this study suggest that benzodiazepines, compared with alternative pharmacologic treatments for common sleep disorders, were associated with an increased risk of drug overdose among young people during the following 6-month period, especially among those with a recent opioid prescription. Drug overdose is an important safety consideration when treating young people with benzodiazepines.
参考来源
- Bushnell GA, Gerhard T, Keyes K, et al. Association of Benzodiazepine Treatment for Sleep Disorders With Drug Overdose Risk Among Young People. JAMA Netw Open. 2022. PMID: 36413369. doi:10.1001/jamanetworkopen.2022.43215
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。